Literature DB >> 9647747

Comparative expression of novel vascular endothelial growth factor/vascular permeability factor transcripts in skin, papillomas, and carcinomas of v-Ha-ras Tg.AC transgenic mice and FVB/N mice.

K L Tober1, R E Cannon, J W Spalding, T M Oberyszyn, M L Parrett, A I Rackoff, A S Oberyszyn, R W Tennant, F M Robertson.   

Abstract

One of the most frequently detected changes in human solid tumors is the mutation of the ras oncogene, which has been associated with production of angiogenic growth factors such as vascular endothelial growth factor/vascular permeability factor (VEGF/VPF). Using the v-Ha-ras Tg-AC transgenic mice and the background FVB/N strain of inbred mice, the pattern of expression of specific VEGF/VPF transcripts was characterized in major organs and in skin, papillomas, and carcinomas during multi-stage skin carcinogenesis. Three VEGF/VPF transcripts were found to be constitutively expressed in skin as well as the major organs in both mouse strains, which corresponded in size and sequence to previously reported murine VEGF120 with a bp size of 331, VEGF164 with a bp size of 333, and VEGF188 with a bp size of 407. A previously unreported fourth murine transcript was also detected in skin and major tissues from both mouse strains which corresponded to rat VEGF144, with a bp size of 404. In addition, a unique 425 bp VEGF transcript which corresponded to human VEGF205 was present in highly vascularized tissues including heart, lung, liver, kidney, brain, as well in papillomas and carcinomas isolated from v-Ha-ras Tg.AC mice. In contrast, VEGF205 was present only in carcinomas derived from FVB/N mice. An antibody generated from a peptide sequence designed to detect each of the five VEGF/VPF peptides defined by RT-PCR analysis confirmed the existence of these five peptides and confirmed that the murine VEGF205 peptide was selectively expressed in papillomas and carcinomas derived from v-Ha-ras Tg.AC mice. These results demonstrate that there is significant alternative splicing of the murine VEGF/VPF gene during multi-stage carcinogenesis, which results in four commonly expressed VEGF transcripts. In addition, these studies identified a fifth VEGF transcript and peptide at the later stages of tumor promotion and in progression which appears to be linked to the presence of v-Ha-ras.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647747     DOI: 10.1006/bbrc.1998.8787

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Social isolation stress augments angiogenesis induced by colon 26-L5 carcinoma cells in mice.

Authors:  W Wu; J Murata; K Murakami; T Yamaura; K Hayashi; I Saiki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin.

Authors:  J Kishimoto; R Ehama; Y Ge; T Kobayashi; T Nishiyama; M Detmar; R E Burgeson
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

3.  Increased skin papilloma formation in mice lacking glutathione transferase GSTP.

Authors:  Colin J Henderson; Kenneth J Ritchie; Aileen McLaren; Probir Chakravarty; C Roland Wolf
Journal:  Cancer Res       Date:  2011-10-05       Impact factor: 12.701

4.  Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha.

Authors:  D A Elson; G Thurston; L E Huang; D G Ginzinger; D M McDonald; R S Johnson; J M Arbeit
Journal:  Genes Dev       Date:  2001-10-01       Impact factor: 11.361

5.  On the way to total integration of prosthetic pylon with residuum.

Authors:  Mark Pitkin
Journal:  J Rehabil Res Dev       Date:  2009

6.  Differential effects of black raspberry and strawberry extracts on BaPDE-induced activation of transcription factors and their target genes.

Authors:  Jingxia Li; Dongyun Zhang; Gary D Stoner; Chuanshu Huang
Journal:  Mol Carcinog       Date:  2008-04       Impact factor: 4.784

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.